During the past decade, HBDH conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "HBDH" are "Acute Myeloid Leukemia" (2 trials), "Acute Leukemia of Ambiguous Lineage" (1 trials), "C-KIT Mutation" (1 trials), "CEBPA Double Mutation" (1 trials) and "Measurable Disease" (1 trials). Many other conditions were trialed in "HBDH" in a lesser frequency.

Most popular intervention types in "HBDH" are "Drug" (4 trials). Other intervention types were less common.

The name of intervention was led by "Dasatinib" (1 trials), "HAD induction with intermediate dose cytarabine" (1 trials), "L-Asparaginase" (1 trials), "Tyrosine kinase inhibitor" (1 trials) and "Venetoclax, Azacitidine" (1 trials). Other intervention names were less common.

The vast majority of trials in "HBDH" are 4 trials for "All" genders.

Currently, there are NaN active trials in "HBDH". 1 are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in HBDH, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in HBDH, 1 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".